HR Execs on the Move

DEKA Research and Development Corporation

www.dekaresearch.com

 
DEKA Research and Development Corporation is a Manchester, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Jay Burkholder
Product Development Team Leader Profile

Similar Companies

Synaptogenix

Synaptogenix is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders.

Pebble Labs

Pebble Labs Inc. is a biotechnology company developing solutions to safely and sustainably increase natural crop yield and food security. Our mission is to develop breakthrough disruptive technologies that address the greatest agricultural, aquacultural, and environmental challenges facing the globe.

Sanford Jackson Medical Center

Sanford Jackson Medical Center is a Jackson, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

BioShield Technologies

BioShield Technologies is a Norcross, GA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Arcutis

Arcutis was founded in 2016 to address significant unmet needs in medical dermatology. The company is a clinical-stage biopharmaceutical company focused on developing and commercializing best-in-class products. Our strategy is to exploit recent innovations in inflammation and immunology to bring the best molecules to bear against validated physiologic targets known to treat dermatological diseases and disorders. Our management team has extensive expertise in the development and commercialization of medical dermatology products, having held key leadership roles at a number of leading dermatology companies and, collectively, has successfully developed more than 50 FDA-approved products. We believe that by leveraging our team`s unique experience and demonstrated expertise to identify, develop and commercialize best-in-class molecules against validated targets, we will be able to develop differentiated products in less time, at lower cost, and at substantially lower risk than other approaches. Arcutis` combination of vision, unmet medical need, experienced management and strategic approach has attracted support from leading investors in the life sciences sector.